Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T20:44:31.316Z Has data issue: false hasContentIssue false

Understanding depot antipsychotics: an illustrated guide to kinetics

Published online by Cambridge University Press:  18 December 2013

Jonathan M. Meyer*
Affiliation:
Patton State Hospital, Patton, California, USA; Mental Health Intensive Case Management, VA San Diego Healthcare System, San Diego, California, USA; Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, California, USA; Department of Psychiatry, Loma Linda University, Loma Linda, California, USA
*
*Address for correspondence: Jonathan M. Meyer, 3350 La Jolla Village Drive (116-A), San Diego, CA 92161, USA. (Email: jmmeyer@ucsd.edu)
Rights & Permissions [Opens in a new window]

Abstract

Long-acting injectable (LAI) antipsychotics can have considerable advantages over oral medications for the management of patients with schizophrenia. Despite the high prevalence of treatment nonadherence with oral pharmacotherapy, LAI antipsychotics are significantly underutilized in this patient population. The availability of newer LAI antipsychotic preparations combined with a resurgent interest in the use of typical antipsychotics has rekindled awareness of the value of LAI medications. This article is intended to provide a visual understanding of the various kinetic profiles of LAI antipsychotics to facilitate initiation and greater use of these agents.

Information

Type
CME Review Article
Copyright
Copyright © Cambridge University Press 2013 
Figure 0

Table 1Kinetic properties of depot antipsychotics

Figure 1

Figure 1Ester LAI antipsychotic disposition.12

Figure 2

Figure 2Single dose kinetic profile of fluphenazine decanoate (25 mg).12

Figure 3

Figure 3Plasma fluphenazine levels during chronic dosing with fluphenazine decanoate 25 mg every 2 weeks.14

Figure 4

Figure 4Relationship between plasma fluphenazine levels and estimated probability of improvement (gray line) and disabling side-effects (black line).18

Figure 5

Figure 5Plasma levels with weekly loading of 50 mg fluphenazine decanoate.23

Figure 6

Figure 6Haloperidol decanoate kinetics and tolerability by plasma level (mean dose 243 mg).12

Figure 7

Figure 7Single dose kinetics of LAI risperidone (25 mg) (data on file, Janssen Pharmaceutica).

Figure 8

Figure 8Comparison Peak and Trough Plasma Levels: 2 mg oral vs 25 mg LAI risperidone every 2 weeks (Ereshefksy L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics, J Clin Psychiatry. 64 (suppl 16), 18–23, 2003. Copyright 2003, Physicians Postgraduate Press. Adapted or Reprinted by permission.)12

Figure 9

Figure 9Kinetics of paliperidone palmitate using standard loading regimen.43

Figure 10

Figure 10Olanzapine pamoate kinetics.47

Figure 11

Figure 11Kinetic profiles of severe sedation cases with olanzapine pamoate.49 (a) Single detailed case example, (b) multiple examples.

Figure 12

Figure 12Kinetic profile of aripiprazole monohydrate (Data on File Otsuka Pharmaceutical Co., Ltd., Presented at APA 2011).54